Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1996-01-03
1997-12-09
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424465, 424468, 424489, 514682, A61K 920
Patent
active
056957742
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/EP94/02300, filed Jul. 11, 1994.
The present invention relates to a method for the treatment of cognitive disorders such as alzheimers disease and to a compound for use in such method.
U.S. Pat. No. 4,420,639 describes 4-(6'-methoxy-2'-naphthyl)butan-2-one (nabumetone) and its use in the treatment of rheumatic and arthritic conditions. It is known that the active metabolite of nabumetone is 6-methoxynaphthyl acetic acid or 6MNA. It should be appreciated that the term 6MNA also includes pharmaceutically acceptable salts thereof.
U.S. Pat. No. 5,192,753 (McGeer) describes the use of NSAID's to treat dementia, however, there is no mention of nabumetone in this patent.
It has now been discovered that nabumetone has potential therapeutic utility for treating and/or prevention of dementia such as alzheimers disease.
Accordingly, the present invention provides a method for treating and/or preventing dementia such as alzheimers disease in human or non-human animals, which comprises administering an effective, non-toxic amount of nabumetone or 6MNA, to human or non-human animals in need thereof.
The present invention also provides the use of nabumetone or 6MNA in the manufacture of a medicament for use in the treatment and/or prevention of dementia such as alzheimers disease.
A nabumetone or 6MNA medicament, for use in the treatment and/or prevention of dementia such as alzheimers disease may be prepared by admixture of nabumetone or 6MNA with an appropriate carrier, which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
Preferably, the medicament is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment and/or prevention of dementia such as alzheimers disease.
The suitable dosage range for nabumetone or 6MNA depends on the severity of the dementia such as alzheimers disease and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
Nabumetone or 6MNA may be formulated for administration by any route, and examples are oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of nabumetone.
The medicaments may, for example, be in the form of tablets, dispersible tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
The medicaments, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycerine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
Solid medicaments may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute nabumetone throughout those medicaments employing large quantities of fillers. When the medicament is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The medicament may also be in the form of an ingestible capsule, for example of gelatin containing nabumetone if desired with a carrier or other excipients.
Medicaments for oral ad
REFERENCES:
patent: 4061779 (1977-12-01), Lake et al.
patent: 4420639 (1983-12-01), Lake et al.
patent: 5192753 (1993-03-01), McGeer et al.
The Lancet, vol. 335, No. 8696, 28 Apr. 1990.
Benston, Jr. William E.
Lentz Edward T.
Page Thurman K.
SmithKline Beecham p.l.c.
Venetianer Stephen
LandOfFree
Use of nabumetone or 6-methoxynaphthyl acetic acid for the treat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of nabumetone or 6-methoxynaphthyl acetic acid for the treat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nabumetone or 6-methoxynaphthyl acetic acid for the treat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1605635